Abiopharma

🔍 Kurtz Ronald M MD (Executive)

Company: RxSight, Inc. (RXST)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 13,425 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: M | equity_swap_involved: false | shares_owned_after: 76,875.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,100 shares of Common Stock at $6.96 per share (Direct)
  Date: 2026-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 71,775.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 764,610.00 | Footnotes: F3
• Sold 13,425 shares of Restricted Stock Unit (Derivative)
  Date: 2026-08-31 | Code: M | equity_swap_involved: false | shares_owned_after: 67,120.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
• F3: Shares held by Cricklewood LP. The Reporting Person is the manager of the general partner of Cricklewood LP and shares voting and investment control of the general partner of Cricklewood LP with his spouse.
• F4: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan (the "Plan")) through each applicable date, one-sixth (1/6th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029.